Target Price | $23.79 |
Price | $7.65 |
Potential |
210.97%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Pharming Group N.V. - ADR 2025 .
The average Pharming Group N.V. - ADR target price is $23.79.
This is
210.97%
register free of charge
$37.00
383.66%
register free of charge
$16.20
111.72%
register free of charge
|
|
A rating was issued by 5 analysts: 5 Analysts recommend Pharming Group N.V. - ADR to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2025 of
210.97%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 245.70 | 283.20 |
19.43% | 15.26% | |
EBITDA Margin | -4.49% | 0.20% |
173.42% | 104.45% | |
Net Margin | -4.42% | 2.40% |
163.80% | 154.33% |
5 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2024 . The average Pharming Group N.V. - ADR sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2024. The average Pharming Group N.V. - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.16 | 0.10 |
176.19% | 162.50% | |
P/E | 76.50 | |
EV/Sales | 1.67 |
Based on analysts' sales estimates for 2024, the Pharming Group N.V. - ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Pharming Group N.V. - ADR...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.